A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities.
Author(s): Gokmen T, Oguz SS, Bozdag S, Erdeve O, Uras N, Dilmen U
Affiliation(s): Neonatal Intensive Care Unit, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey.
Publication date & source: 2011-05-12, J Perinatol., [Epub ahead of print]
Objective:To compare the effectiveness of oral erythromycin versus ursodeoxycholic acid (UDCA) treatment in preventing feeding intolerance and liver function abnormalities.Study Design:A prospective, double blind, randomized, controlled trial in which three groups of preterm infants (birth weight <1500 g) were randomized to erythromycin (12.5 mg kg(-1) per day), UDCA (5 mg kg(-1) every 6 h) or placebo treatment. During the period 352 infants were admitted to our unit of which 75 infants whose parents accepted participation were enrolled in the study. Full enteral feeding or intestinal failure-associated liver disease was considered as the primary outcome measures.Results:Time to achieve full feeding after beginning the treatment was significantly shorter in the erythromycin group (P=0.014). gamma-Glutamyl transpeptidase levels in the placebo group were significantly higher than in the intervention groups (P=0.001). GTT level was slightly lower in UDCA groups than erythromycin.Conclusion:Oral erythromycin was most effective in facilitating enteral feeding and UDCA was most effective in preventing cholestasis in very low birth weight infants. Prophylactic usage of UDCA could be considered in infants with prolonged parenteral nutrition.Journal of Perinatology advance online publication, 12 May 2011; doi:10.1038/jp.2011.56.